The Use Of MicroRNA As Novel Therapeutic Targets For Reducing Retinal Inflammation And Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$349,076.00
Summary
Age-Related Macular Degeneration (AMD) is the most common cause of blindness in Australia. We aim to investigate a new class of potential therapeutics, microRNA which are involved in the regulation of many biological processes, including inflammation. A greater understanding of these miRNA will enable discovery of novel therapeutic targets for inflammatory diseases like AMD, and will have further reaching applications in other inflammatory disease such as Alzheimer’s and Parkinson’s.
The vision we rely on every day to read and recognise faces depends upon the health of the central portion of our retina, the macula. Age-related Macular Degeneration (AMD) is the leading cause of blindness in Australia and the western world. Researchers at the Australian National University are collaborating to bring a new test for AMD severity to the market within 3 years. The objective is to provide doctors with a rapid, cost-effective tool to help them manage treatment.
Novel Functional Testing For Early Diabetic Retinopathy
Funder
National Health and Medical Research Council
Funding Amount
$447,578.00
Summary
About 7.5% of Australians have diabetes and 62% of them will have signs of damage to their eyes within 6 years of diagnosis. Diabetes is 2 to 3 times more common amongst Aboriginal Australians. A group of researchers at the Australian National University are collaborating to bring a new test for the severity of diabetic eye disease to the market within 3 years. The objective is to provide doctors with a rapid, cost-effective tool to help them recognize sight-threatening damage and to assist in t ....About 7.5% of Australians have diabetes and 62% of them will have signs of damage to their eyes within 6 years of diagnosis. Diabetes is 2 to 3 times more common amongst Aboriginal Australians. A group of researchers at the Australian National University are collaborating to bring a new test for the severity of diabetic eye disease to the market within 3 years. The objective is to provide doctors with a rapid, cost-effective tool to help them recognize sight-threatening damage and to assist in treatment.Read moreRead less